NEW YORK (GenomeWeb News) – Celera said today that it has licensed the rights to use Medical Therapies Limited's patent portfolio for the protein midkine in its lung cancer diagnostics programs.

Under the exclusive license with Sydney-based Medical Therapies, Celera will pay up front and milestone payments and royalties on product sales over the life of the patents. Specific financial details were not disclosed by the firms.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.